On the stock market since 2020, it operates in the world of health and science. It has 1,300 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 76% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 36% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 52% a year on average.
Sales run at $493.6M a year. A small number, but proof the product has real buyers.
There is $115.5M in the vault; even if every debt were paid off, $83.4M would remain.
A loss of $1.6M against $493.6M in annual sales.
Over the last 12 months, executives reported 169 sells against just 27 buys. Not an alarm bell by itself, but a number worth watching.
The stock trades 16% above the average analyst price target.
On our five-subject report card, NARI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NARI is a high-risk stock — not yet profitable, and its future rides on its product catching on.